



AN INITIATIVE FROM ALK-ABELLO INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

EURneffy® 2 mg Nasal Spray

For the emergency treatment of anaphylaxis
in patients ≥ 30 kg⁶

INNOVATIVE

The only needle-free,
ready-to-use nasal
adrenaline⁶

PROVEN

Approved in the
UK based on
clinical and
pharmacological
studies^{6,7}



CONVENIENT


Temperature-
stable with
a shelf-life
of up to
30 months⁶

See page 5 for prescribing information and
adverse event reporting details

Understanding anaphylaxis

Anaphylaxis is a severe, potentially life-threatening allergic reaction that requires prompt administration of adrenaline.

THE MECHANISM OF ANAPHYLAXIS¹



MANY PATIENTS DO NOT USE ADRENALINE DURING ANAPHYLAXIS

Adrenaline auto-injectors are widely prescribed for people with severe allergies but delays in administration of adrenaline, or failure to administer at all, are associated with increased risk of hospitalisation and in some cases, death.^{2,3}

Hesitation is often linked to uncertainty about whether adrenaline is needed.⁵

52%

of patients did not use their adrenaline auto-injector when it was needed in their most severe allergic reaction^{2*}

*Survey in the US of adults (n=450), parents of children (n=255) and adolescents (n=212) who had been prescribed an adrenaline auto-injector.²

† UK-based questionnaire study of children and teenagers (n=969) prescribed an adrenaline auto-injector.³

83%

of young patients experiencing an episode of anaphylaxis did not use their adrenaline auto-injector despite experiencing potentially life-threatening symptoms.^{3†}



EURneffy®

2 mg nasal adrenaline spray

Severe allergic reactions, including anaphylaxis, can be triggered by insect stings or bites, foods, medicinal products or other allergens, as well as idiopathic or exercise-induced anaphylaxis.⁶

For patients ≥ 30 kg at risk, **EURneffy®** is the only needle-free and ready-to-



use nasal adrenaline for the immediate treatment of severe allergic reactions, including anaphylaxis.⁶

The compact nasal spray delivers adrenaline (epinephrine) for rapid absorption as an emergency treatment.⁶

How EURneffy® works

- Adrenaline (epinephrine) is absorbed intranasally⁶
- It binds to adrenergic receptors, reducing the anaphylactic reaction⁴
- This constricts blood vessels, raises blood pressure and improves blood flow to vital organs⁴
- **EURneffy®** contains Intravail® (dodecylmaltoside), an absorption enhancer that supports rapid intake^{4,6}
- The single-dose spray device has been used for more than 20 years for other intranasal medications, including naloxone⁴

Training materials and guidance on using EURneffy® are available at <https://eurneffy.co.uk/>

EURneffy® clinical data and safety profile

CLINICALLY SUPPORTED

EURneffy® has been approved in the UK following pharmacokinetic (PK) and pharmacodynamic (PD) studies.⁶

The clinical evaluation of risk and benefit is based on the assessment of the PK and PD profiles, as prospective, randomised, controlled trials are not feasible in patients experiencing a severe allergic response.⁴

EURneffy® was evaluated in multiple clinical pharmacology studies in adults and paediatric subjects (≥30 kg).^{4,6}

PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE

Studies assessed plasma adrenaline concentrations after nasal administration of EURneffy®, characterising its pharmacokinetic and pharmacodynamic profiles in clinical trials.⁶

SAFETY PROFILE

EURneffy® was well tolerated across studies.⁶ No serious adverse events were reported; most reactions were mild and short-lived, primarily local nasal symptoms or transient systemic effects.⁶

ONE DOSE

Common (≥ 1/100 to < 1/10) adverse reactions: rhinorrhoea, nasal oedema, nasal pain, nasal congestion, increased blood pressure, increased heart rate, anxiety, tremor, palpitations.⁶

ADDITIONAL DOSE

Very common (≥ 10% of patients) adverse reactions were only reported in clinical studies after the second 2 mg dose (4 mg in total): throat irritation (18.8%), headache (17.6%), nasal discomfort (12.9%), feeling jittery (10.6%).⁶



SUMMARY OF FINDINGS Clinical studies assessed EURneffy® pharmacokinetics and pharmacodynamics, including plasma adrenaline concentrations and changes from baseline in systolic blood pressure and pulse rate.^{4,6} In healthy volunteers, time to maximum plasma concentration was 20 to 30 minutes⁶

Summary

EURneffy® provides an intranasal route for delivering adrenaline in the emergency treatment of severe allergic

reactions, including anaphylaxis.⁶ No adverse drug reactions observed in clinical studies were serious.⁶

REFERENCES

- 1 Resuscitation Council UK. Emergency treatment of anaphylactic reactions. 2021.
- 2 Warren CM et al. Ann Allergy Asthma Immunol. 2018;121(4):479–489.
- 3 Noimark L et al. Clin Exp Allergy. 2012;42(2):284–292.
- 4 Ellis AK et al. Pharmaceutics. 2024;16(6):811.
- 5 Chooniedass R et al. Ann Allergy Asthma Immunol. 2017;119(2):108–110.
- 6 EURneffy® Summary of Product Characteristics. ALK-Abelló Ltd. June 2025.
- 7 Fleischer DM et al. J Allergy Clin Immunol Pract. 2025;13(6):ePub ahead of print.

Further information and contacts

PRESCRIBING INFORMATION



Prescribing information for EURneffy® (2 mg nasal adrenaline) is available via QR code and as a PDF

REPORT ADVERSE EVENTS

Adverse events should be reported. Find reporting forms and information at yellowcard.mhra.gov.uk

Adverse events should also be reported to ALK-Abelló Ltd at drugsafetyuk@alk.net or T: +44 118 903 7940

ABOUT ALK

ALK is a global allergy solutions company with more than 100 years of experience in allergy prevention, diagnosis and treatment.

The company combines scientific expertise with practical solutions for patients, their families and healthcare professionals.

ALK provides treatments, products and educational resources to help make managing allergy simpler and more effective.



ALK-ABELLÓ LTD

2nd Floor, The Place
Bridge Avenue
Maidenhead SL6 1AF

T: +44 118 903 7940

E: infouk@alk.net

W: www.alk.net